Catechol-O-methyltransferase

Fromage from Europe: Similar, But Not the Same How to tell the difference between France's most iconic cheeses

Retrieved on: 
Monday, October 10, 2022
North American Meat Processors Association, Catechol-O-methyltransferase, Camembert, Farmer, Butter, Council, Milk, Emmental, REA, Cheese, Awareness, Ageing, Goat milk, Roquefort, European Commission, Bleu d'Auvergne, Penicillium roqueforti, Alpine, Dairy product, Coulommiers, Brie, European, Fromage

These tips will help you to tell the difference between cheeses in four Fromage from Europe families.

Key Points: 
  • These tips will help you to tell the difference between cheeses in four Fromage from Europe families.
  • Brie , Camembert and Coulommiers are all soft-ripened, cow's milk cheeses aged for about four weeks.
  • Brie is shaped into large wheels, Camembert in small wheels, and the size of Coulommiers is in between the two.
  • The content of this promotion campaign represents the views of the author only and is his/her sole responsibility.

Athletico Physical Therapy Opens in Martinsville

Retrieved on: 
Thursday, August 5, 2021
Headache, Athletico Physical Therapy, Diagnosis, PT, Catechol-O-methyltransferase, Insurance, Injury, Therapy, Dry needling, Health, Patient, Growth, The Chartered Institute of Ergonomics and Human Factors, COVID-19, Pain, Communication, Physical, Clinic, White Castle, Walmart, Risk, DPT, Medical imaging, Health insurance, Medicine

MARTINSVILLE, Ind., Aug. 5, 2021 /PRNewswire/ -- Athletico Physical Therapy has opened a new location in Martinsville and is conveniently located between White Castle and Steak 'n Shake near Walmart Supercenter.

Key Points: 
  • MARTINSVILLE, Ind., Aug. 5, 2021 /PRNewswire/ -- Athletico Physical Therapy has opened a new location in Martinsville and is conveniently located between White Castle and Steak 'n Shake near Walmart Supercenter.
  • In addition to in-clinic treatment at the Martinsville clinic, Athletico is also offering telehealth virtual treatment options where patients can connect with a Physical Therapist through a secure online video chat.
  • "I chose physical therapy as my profession because it provides excellent patient outcomes, allows the opportunity to specialize in active medicine and overall it's fun," said Elysia Tieman, PT, DPT, COMT and Clinic Manager of Athletico Martinsville.
  • Services available at Athletico Martinsville include:
    Physical therapy Our physical therapists treat you to reduce pain, improve or restore mobility, and to help you remain at your optimal health without further risk of injury.

Boehringer Ingelheim and The Lieber Institute for Brain Development to Collaborate to Develop Centrally Acting COMT Inhibitors for Treatment of Neuropsychiatric Disorders

Retrieved on: 
Tuesday, March 16, 2021
Mental health, Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Medical specialties, Catechol-O-methyltransferase, Branches of biology, Clinical medicine, Lieber Institute for Brain Development, Parkinson's disease, Boehringer Ingelheim, Neuropsychiatry

Boehringer Ingelheim and the Lieber Institute for Brain Development (LIBD) today announced a joint research and licensing collaboration focused on the development of novel centrally acting COMT (catechol-O-methyltransferase) inhibitors for the potential treatment of cognitive deficits in a spectrum of neuropsychiatric disorders, including schizophrenia.

Key Points: 
  • Boehringer Ingelheim and the Lieber Institute for Brain Development (LIBD) today announced a joint research and licensing collaboration focused on the development of novel centrally acting COMT (catechol-O-methyltransferase) inhibitors for the potential treatment of cognitive deficits in a spectrum of neuropsychiatric disorders, including schizophrenia.
  • While peripherally acting COMT inhibitors are currently used as an adjunctive therapy in the treatment of neurological conditions, including Parkinsons disease, this new collaboration is investigating centrally acting COMT inhibitors in neuropsychiatric disorders.
  • Recent studies from the Lieber Institute suggest an important role of centrally acting COMT inhibitors in the potential symptomatic treatment of various neurological and neuropsychiatric disorders.
  • In partnering with the Lieber Institute, Boehringer Ingelheim has in-licensed preclinical pipeline candidates, representing a first-in-class approach for targets in neuropsychiatric disorders.

Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease

Retrieved on: 
Wednesday, July 10, 2019
Phenols, Aromatic compounds, Chemical compounds, Catechols, Nitrophenols, Neurocrine Biosciences, Opicapone, Catecholamines, Catechol-O-methyltransferase, Bial, Parkinson's disease, Neurocrine

With opicapone, we aim to prolong the benefits of levodopa by providing a new treatment option to patients with Parkinson's disease in the U.S.," said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences.

Key Points: 
  • With opicapone, we aim to prolong the benefits of levodopa by providing a new treatment option to patients with Parkinson's disease in the U.S.," said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences.
  • We look forward to working with the FDA to bring this new treatment option to patients coping with this debilitating disorder."
  • Neurocrine Biosciences in-licensed opicapone from BIAL in 2017 and has exclusive development and commercialization rights in the U.S. and Canada.
  • Opicapone, an investigational treatment for Parkinson's disease in the U.S., is a novel, once-daily, selective catechol-O-methyltransferase (COMT) inhibitor.

The Global Market for Parkinson's Disease Drugs to 2024 - COMT (Catechol-O-Methyltransferase) Inhibitors to Register Robust Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, May 10, 2019
Health, Pharmaceutical, Aromatic compounds, Organic compounds, Catechols, Catechol-O-methyltransferase inhibitor, Nitrophenols, Catechol-O-methyltransferase, Tolcapone, Entacapone, Parkinson's disease, Pharmacological treatment of Parkinson's disease, Carbidopa/levodopa/entacapone

The "Parkinson's Disease Drugs Market - Growth, Trends, and Forecast (2019-2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Parkinson's Disease Drugs Market - Growth, Trends, and Forecast (2019-2024)" report has been added to ResearchAndMarkets.com's offering.
  • Parkinson's disease drugs market is expected to witness significant growth, owing to the increasing cases of Parkinson's disease, with the growth in aging population levels.
  • The two most common COMT inhibitors, used in the treatment of Parkinson's disease, are Comtan (entacapone) and Tasmar (tolcapone).
  • The sheer number of Parkinson's disease patients, combined with the availability of reimbursements and high awareness, is boosting the growth of the market.